Replies to post #155539 on Cytodyn Inc (CYDY)

[kgromax]

PR numbers are at best wrong, at worst manipulated

The reason is the following: the survival % numbers at 14 days don't match the CD12 previously published survival % numbers at 28 days for critically-ill patients.

The new PR just said that critically-ill Leronlimab (=SOC+Leronlimab) patients had a survival x5 times higher than placebo (=SOC) patients. So placebo patients had a survival at 14 days <20% obviously...

... but the CD12 initial 8-K SEC filing said that the criticaly-ill placebo (=SOC only) patients had a survival of ... 63%.

How can <20% of patients be alive at 14 days, yet 63% of these patients be alive at 28 days ?

Either the dead don't die (some patients were just raised from the dead!), or, Cytodyn made yet another obvious mistake in their PR (not impossible, they did correct past PRs already) or ... they did not disclose yet another subgroup-in-a-subgroup data-mining performed (without correcting the p-values for data mining of course!!!). This PR is manipulative and will be a treat for any class action or SEC lawyer.